Start with the decision the test will change
A diagnostic test can produce an impressive result in a study and still leave an important practical question unanswered: what happens to the person after the result arrives?
In an October 21 departmental update, WHO announced guidance for generating evidence about new tuberculosis tests, specimen types and testing strategies. The update describes attention to study design, participant selection, sample size and reporting, alongside patient-important outcomes, values, cost-effectiveness, equity, acceptability and feasibility.
The distinction is useful. Evidence about whether a test identifies disease is essential. Evidence about its place in a care pathway asks an additional question. The announcement describes a framework linking the diagnostic's clinical role to the design and reporting of studies; it does not recommend or approve a particular new product.
An accuracy estimate needs its setting
The authors of STARD 2015, the diagnostic-accuracy reporting standard, identify 30 reporting items and explain why recruitment, clinical context and the reference standard matter. Those details help readers understand what a reported accuracy estimate describes. The paper is methodological background from 2015, not new TB-specific evidence.
Maya's analysis: A useful test report should let a reader identify who was studied, which condition the test was intended to detect and what comparison determined the study's disease classifications. Without that context, the same headline percentage can invite very different interpretations.
Consider a deliberately hypothetical report saying a test correctly identified nine of ten people with disease. That describes performance in ten people who had disease. It does not tell us how many people without disease received a positive result, how uncertain the estimate is, or whether the participants resemble those who would use the test elsewhere. The example is explanatory arithmetic, not a result for a real TB product.
Diagnosis is part of a sequence
WHO's TB fact sheet, dated March 24, 2026, recommends rapid diagnostic tests initially for people with signs and symptoms of TB. It also distinguishes disease diagnosis from tests used to identify TB infection and notes the complexities of childhood, HIV-associated and drug-resistant TB. Those are different clinical questions; a claim about one should not quietly become a claim about all of them.
Maya's analysis: Evaluation can follow the intended use from eligibility through specimen collection, an interpretable result and the clinical decision that follows. Researchers can then specify which steps their study actually observes. A study that ends at a laboratory result should be described at that endpoint. A claim about improved treatment or health outcomes needs evidence that follows people further.
This also helps make uncertainty useful. Rather than describing a product simply as promising, coverage can identify which evidence is available and which question remains open. Does the uncertainty concern performance in a particular population, the ability to obtain the specimen, or what happens after diagnosis? Different gaps call for different studies.
The new guidance provides a research agenda to watch. Readers should expect clear descriptions of study populations, comparisons and outcomes before accepting a broad claim of better care. A test's contribution becomes easier to judge when the evidence follows the decision it is supposed to improve.
Linked source notes: WHO announcement, October 21, 2026 supplies the new guidance's described scope. The publication listing is indexed October 20; full-page requests failed, so its listing date is kept separate from the announcement. STARD 2015, DOI 10.1136/bmj.h5527, supplies reporting-method background from the authors' indexed text; full-page access returned 403. WHO TB fact sheet, March 24, 2026 supplies diagnostic context.
How we reported this: AI-assisted comparison of the WHO announcement, official background and indexed primary methodological text. No full-text review of the new guidance or STARD paper is claimed. No diagnostic validation, systematic review, interviews or statistical reanalysis. The hypothetical nine-of-ten example was checked arithmetically and is not clinical advice.
Persona disclosure. Maya Bell is a recurring fictional TiPH editorial pen-name for evidence explainers. Maya Bell is not a real individual or an expert source; no biography, credentials, employment history, lived experience or on-location reporting is implied. AI assisted the research and drafting of this article, and Elijah St. John reviewed and approved it for publication.
Related on TiPH: Global Signal Scan, October 23, 2026 · Latest news · How we verify signals